Uncategorised

EM Imaging obtains global licence for optical agent that detects cancer early

Edinburgh, United Kingdom, 16 th September, 2015 – Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal (bowel) cancer.

EM Imaging, a company which develops and commercialises novel optical imaging agents, recently signed the licensing agreement with GE Healthcare Ltd. and Dyax Inc. EM Imaging will now complete the development of this unique imaging agent “EMI-137” that can help doctors identify colorectal (bowel) cancer early.

In a recent scientific study, reported in the prestigious scientific journal Nature Medicine, the EMI-137 agent allowed doctors to see more early-stage colorectal cancer (CRC) and precancerous tumours, which can then easily be removed via colonoscopy. However, screening with a colonoscope, which is currently the most common method, can miss up to 25% of precancerous growths, especially smaller, flat lesions.

Dr James Hardwick, the lead investigator on the study published in Nature Medicine said:

“Of the 47 precancerous polyps detected in this study, 12 were missed using a standard colonoscope. This underlines how unreliable this method can be, and we therefore welcome life-saving new technology like EMI-137. This agent has the potential to make polyps light up like light bulbs – allowing clinicians to detect and remove more polyps, prevent more cancers and save more lives.”

Evidence that colorectal cancer can be prevented by the removal of pre-cancerous lesions and polyps (abnormal growth of tissue) is strong. The EMI-137 agent can help doctors more easily identify these suspicious lesions, take a sample (biopsy) or remove the lesion completely. Colorectal cancer is the second most common cause of cancer in women and the third most common in men, and is a major cause of death.

The Phase I/IIa study (Nature Medicine Link), in 35 subjects (20 healthy volunteers and 15 patients with high risk of CRC) shows that optical molecular imaging using the fluorescent agent specific for c-Met is feasible and safe.

Fluorescence colonoscopy in patients receiving intravenous EMI-137 enabled the visualisation of all neoplastic polyps that were visible with white light, and additionally, detected previously missed polyps that were not visible with white light alone. This enables the detection of polyps missed by other techniques.

EMI-137 is a water-soluble compound consisting of a 26–amino acid cyclic peptide, conjugated to a fluorescent cyanine dye, that binds to human tyrosine kinase c-Met, a receptor frequently overexpressed during cancer growth. EMI-137 has the potential on intravenous administration to image a wide range of cancers including, breast cancer, oesophageal cancer, ovarian cancer, thyroid cancer, bile duct carcinoma and lung cancer, due to its specific targeting of the c-Met–receptor.

Ian Wilson, CEO of EM Imaging, commented:

“Colorectal cancer is a major cause of death and this new agent has the potential to save thousands of lives through early detection. It gives providers the potential to effectively stratify patients, direct therapy choice and improve patient outcomes, while lowering the costs to the healthcare system. The team is extremely motivated to complete this product’s development and get it into the hands of clinicians in order to benefit patients. In addition EM Imaging will explore the utility of this new agent to visualise tumours during surgery, with studies planned to begin before the end of 2015.”

Sian Godwin, Head of Licencing at GE Healthcare, said:

“We’re pleased EM Imaging will develop and commercialise GE-137, as optical agents can be useful in clinical and research settings for a wide range of common diseases. We see broad partnership and licencing across our research and development portfolio as a way to increase access to new technologies in precision medicine, help develop better diagnostics for patients and reduce the cost of healthcare.”

Dr Neville Young, Programme Manager, Colorectal Therapies Healthcare Technologies Cooperative, said:

“The NIHR funded Colorectal Therapies HTC, based at the University of Leeds drives a national network of clinicians and academics who are funded to support the development innovative new technologies that have the potential to benefit patients affected by colorectal disease. We are excited to be working with EM Imaging to help demonstrate both the cost effectiveness and clinical efficacy of their new colorectal tumour tagging peptide. This technology offers the possibility to identify and remove more easily any cancerous polyps in a patient undergoing a colonoscopy.”

adminEM Imaging obtains global licence for optical agent that detects cancer early
read more

Edinburgh Molecular Imaging Ltd appoints new Chairman

Edinburgh, United Kingdom, 2nd September 2015 – The Board of Edinburgh Molecular Imaging Ltd (EM Imaging) is pleased to announce the appointment of John Jeans CBE CEng as non-executive Chairman with effect from 31st August 2015.

In an industrial career spanning 35 years John held senior international leadership positions in global companies including Smith & Nephew, Bristol Myers Squibb, Johnson & Johnson and Amersham plc (now GE Healthcare). John headed the commercial function of GE’s Life Science business and was the Chairman of its UK Healthcare Company. His domain expertise ranges from medical devices and pharmaceuticals to in-vivo and in-vitro diagnostics; encompassing research, product development, manufacturing and commercialisation.

John is Chairman of the Council of Cardiff University and Imanova. In addition he chairs the Board of UK Biocentre Ltd, is a non-executive Director of Renishaw plc and a Board member of the University and College Employers Association.

An advisor to public and third sector organisations, he was appointed by the Prime Minister in 2014 as the UK Government’s Life Science Champion for medical technology. John leads Innovate UK’s Stratified Medicine Advisory Board and the KTN’s Health Board, and has sat on advisory panels for the MRC, EPSRC, NIHR and the Wellcome Trust. He has served on several Government bodies including Co-Chairing a Ministerial Committee on Medical Technologies, is an inaugural member of the Science Advisory Council for Wales and a founder Trustee of the Francis Crick Institute. He is also Chair of the Strategic Advisory Panel for the Singapore Government’s Diagnostics Hub.

John was previously the Deputy Chief Executive of the Medical Research Council, a member of its Audit and Risk Committee and Chaired the Trustee Board of MRC Technology.

He was awarded a CBE for services to Life Sciences, Healthcare and Science in 2012.

Commenting on the changes to the Board, Ian Wilson, CEO of EMI, said:

“I am delighted to welcome John to the Board.  With his extensive experience in the healthcare and diagnostics sector John is an extremely valuable addition to the Company. His deep expertise and leadership skills will be central to supporting EM Imaging in bringing its novel optical imaging technology to the forefront of the global molecular imaging market.”

John Jeans said:

“The team at Edinburgh Molecular Imaging have made great progress in establishing a strong portfolio of optical imaging opportunities and it’s a privilege to be joining the Company as it enters this exciting period of further development”.

Further information:

 

Edinburgh Molecular Imaging

Ian Wilson, CEO:  info@emimaging.com

 

PLMR (Press Team)

Anokhi Madhavji: +44 (0)7415 701567

adminEdinburgh Molecular Imaging Ltd appoints new Chairman
read more

Highly specific, multi-branched fluorescent reporters for analysis of human neutrophil elastase

Human neutrophil elastase (HNE) is a serine protease implicated in the pathogenesis of acute and chronic inflammatory disease. Here a series of, internally quenched, single fluorophore fluorescent reporters were synthesised that allowed the rapid, highly specific and sensitive analysis of HNE activity over closely related proteases.

adminHighly specific, multi-branched fluorescent reporters for analysis of human neutrophil elastase
read more